This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Copper

Essential trace mineral, RDA 900 mcg/day, UL 10 mg/day (US) or 5 mg/day (EFSA 2023).

Aliases (3)

COPPER · COPPER BISGLYCINATE · CUPRIC OXIDE

TYPICAL DOSE

2 mg copper bisglycinate / day sits at 12

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is Copper?

Essential trace mineral, RDA 900 mcg/day, UL 10 mg/day (US) or 5 mg/day (EFSA 2023). Solo supplementation rarely needed on a varied diet — but mandatory counterweight for anyone running zinc ≥25 mg/day chronically because zinc induces intestinal metallothionein that preferentially binds and blocks copper absorption. Chronic high-zinc-without-copper → copper-deficiency myeloneuropathy (sub-acute combined degeneration phenotype, frequently irreversible — Kumar 2003, Jaiser & Winston 2010 systematic review of 55 cases). Six cuproenzymes do the heavy lifting: cytochrome c oxidase (mitochondrial ATP), Cu/Zn-SOD (antioxidant), ceruloplasmin (iron mobilization), lysyl oxidase (collagen/elastin cross-linking — tendon-relevant for MMA), dopamine-β-hydroxylase (DA→NE synthesis), tyrosinase (melanin). For Dylan on V4 zinc 25mg/day: add 1-2 mg copper bisglycinate at a different meal. Hard block: Wilson's disease (ATP7B mutation, copper accumulation — rule out before supplementation if family history or symptoms).

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

Research Protocols

Disclaimer: These are commonly discussed research protocols and not medical advice.

Goal

Dose

Frequency

Solo Use

Cycle

Goal:Copper (II) glycinate / copper bisglycinate

Dose:—

Frequency:—

Solo:—

Cycle:—

Goal:Copper gluconate

Dose:—

Frequency:—

Solo:—

Cycle:—

Goal:Copper sulfate (cupric sulfate)

Dose:—

Frequency:—

Solo:—

Cycle:—

Goal:Cupric oxide (CuO)

Dose:—

Frequency:—

Solo:—

Cycle:—

Peptide Interactions

Zinc

Synergistic

(this is the *raison d'être* of the supplementation). 8:1 to 15:1 Zn:Cu mg ratio; separate doses by ≥4h.

Vitamin C / ascorbate.

Synergistic

DBH (NE synthesis) requires both copper and ascorbate as obligate cofactors. Co-sufficiency supports catecholamine biosynthesis. Note: ≥1g vitamin C taken si…

Iron (when iron is needed).

Synergistic

Copper sufficiency is required for ceruloplasmin-mediated iron mobilization. Iron supplementation in a copper-deficient subject is futile until copper is res…

Manganese, selenium, B-complex.

Synergistic

All trace-mineral cofactor co-sufficiencies for metalloenzyme function. No specific synergy with copper, but a balanced micronutrient base is the right hygiene.

Zinc

Avoid

(same-dose) — covered above. Separate by 4-6h.

High-dose vitamin C

Avoid

(≥1g same-dose) — separate by 2h.

High-dose calcium

Avoid

(≥600 mg same-dose) — modest reduction in copper absorption; separate by 2h.

High-dose molybdenum

Avoid

(>1 mg/day) — molybdenum can complex with copper (the basis of the Wilson's drug tetrathiomolybdate). Not a practical concern at supplement doses but worth n…

Antacids / PPIs chronically

Avoid

gastric acid is needed for copper liberation from food/supplement matrix. Long-term PPI use modestly impairs copper absorption.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Side Effects & Safety 3

Side Effects

1None at maintenance doses 1-2 mg/day in healthy adults with bisglycinate or gluconate forms.
2GI: nausea, metallic taste, abdominal discomfort — most common with cupric sulfate or empty-stomach dosing; uncommon with bisglycinate + food.
3Mild headache — occasional; usually transient with consistent dosing.

When to Stop

Acute high-dose toxicity (>10 mg single dose or sustained >10-30 mg/day intake) — nausea, vomiting, abdominal pain, hemolytic anemia, hepatotoxicity, renal injury. Reports of acute liver failure at sustained 30-60 mg/day (case reports). Not a realistic risk at maintenance doses; relevant only if accidentally consuming multiple high-copper supplements.
Wilson's disease decompensation if undiagnosed. Wilson's is recessive ATP7B mutation, ~1/30,000 carrier frequency. Untreated patients accumulate copper in liver → cirrhosis; brain → tremor, dysarthria, dystonia, psychiatric symptoms. Hallmark: Kayser-Fleischer rings in cornea (slit-lamp exam). Supplementing copper in undiagnosed Wilson's accelerates pathology. Rule out if family history, unexplained transaminitis under 40, neurologic symptoms.
Liver enzyme elevation at sustained 10 mg/day (EFSA 2023 data) — transient, resolves on cessation, but signals approach to UL.
Theoretical Alzheimer's concern (older adults). Some observational data link elevated unbound/non-ceruloplasmin-bound serum copper with Alzheimer's pathology (amyloid metal chemistry). Mechanism debated. Practical takeaway for young athletes: not relevant at maintenance doses. Practical takeaway for 65+ adults: aim for adequacy via diet, not supraphysiologic supplementation.
First 1-2 weeks of supplementation: GI tolerance check. If nausea/metallic taste persists, switch form (sulfate → bisglycinate) or take with larger meal.
First 3-6 months of zinc + copper co-supplementation: Confirm the regimen is actually preventing deficiency — re-check ceruloplasmin + serum copper if doing labs. For Dylan, this overlaps the June 2026 bloodwork window — useful baseline.
Annual monitoring while on chronic combo: Serum copper + ceruloplasmin + CBC q12 months at minimum.

References

Kumar N, Gross JB Jr, Ahlskog JE. Myelopathy due to copper deficiency. Neurology. 2003;61(2):273-274. PMID 12874423

pubmed.ncbi.nlm.nih.gov · 2003

foundational case series; CDM as treatable myelopathy.

Copper

Overview

What is Copper?

Pharmacokinetics

Research Protocols

Peptide Interactions

What to Expect

Side Effects & Safety 3

Side Effects

When to Stop

References

Kumar N, Gross JB Jr, Ahlskog JE. Myelopathy due to copper deficiency. Neurology. 2003;61(2):273-274. PMID 12874423

Hedera P, Fink JK, Bockenstedt PL, Brewer GJ. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin. Arch Neurol. 2003;60(9):1303-1306. PMID 12975299

Willis MS, Monaghan SA, Miller ML, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol. 2005;123(1):125-131. PMID 15762288

Spinazzi M, De Lazzari F, Tavolato B, Angelini C, Manara R, Armani M. Myelo-optico-neuropathy in copper deficiency occurring after partial gastrectomy. J Neurol. 2007;254(8):1012-1017. PMID 17415508

Jaiser SR, Winston GP. Copper deficiency myelopathy. J Neurol. 2010;257(6):869-881. PMID 20232210

Goodman BP. Copper Deficiency Myelopathy (Human Swayback). Mayo Clin Proc. 2011;86(10):1003-1006

Copper deficiency myelopathy mimicking cervical spondylitic myelopathy: a systematic review of the literature with case report. Spine Journal. 2024

EFSA Panel on Nutrition. Re-evaluation of the existing health-based guidance values for copper and exposure assessment from all sources. EFSA Journal. 2023;21(1):7728

NIH Office of Dietary Supplements: Copper Health Professional Fact Sheet

Linus Pauling Institute: Copper Micronutrient Information Center

Wilson Disease — AASLD Practice Guidance update 2023 (PMC 10187853)

Wilson Disease GeneReviews (NCBI Bookshelf NBK1512)

Dopamine beta-hydroxylase — Wikipedia (with cited primary refs on copper-cofactor biology)

Milewska M et al. Copper Does Not Induce Tenogenic Differentiation but Promotes Migration and Increases Lysyl Oxidase Activity in Adipose-Derived Mesenchymal Stromal Cells. Stem Cells Int. 2020. PMID 32148523

Mocchegiani E, Malavolta M. Plasma copper/zinc ratio: an inflammatory/nutritional biomarker as predictor of all-cause mortality in elderly population. PMID 19821050

Wahab A et al. Zinc-induced copper deficiency, sideroblastic anemia, and neutropenia: A perplexing facet of zinc excess. Clin Case Rep. 2020. PMID 32983473

Zinc containing dental fixative causing copper deficiency myelopathy. PMC 5534901

Copper Bisglycinate complete science-based guide 2026 — DietarySupplementDB

Relative bioavailability of organic bis-glycinate bound copper (PMC 8188816)

Supplementing Copper at the Upper Level of the Adult Dietary Recommended Intake — J Nutr 2022

See something off?

Related compounds